Nurel Therapeutics

Nurel Therapeutics is a preclinical-stage biotechnology company focused on developing long-term genomic therapies for chronic pain and other neurological disorders. The company utilizes a proprietary non-replicating Herpes Simplex Virus (HSV) vector platform to deliver therapeutic genes directly to the peripheral nervous system. Its lead program, NT-1, is designed to provide sustained relief for chronic pain by expressing proenkephalin, a natural opioid peptide, in targeted nerve cells. By leveraging the natural neurotropism of HSV, Nurel aims to provide a non-addictive alternative to systemic opioids. The company is a majority-owned subsidiary of Bio-Bridge Science and maintains strong ties to the University of Pittsburgh.